Powder X-ray diffraction of nintedanib esylate hemihydrate, (C 31 H 33 N 5 O 4 )(C 2 H 5 O 3 S)(H 2 O) 0.5
Source abstract
Abstract
The crystal structure of nintedanib esylate hemihydrate was refined using synchrotron X-ray powder diffraction data and optimized using density functional theory techniques. Nintedanib esylate hemihydrate crystallizes in space group P-1 (#2) with a = 11.5137(1), b = 16.3208(4), c = 19.1780(5) Å, α = 69.0259(12), β = 84.4955(8), γ = 89.8319(6)°, V = 3347.57(3) Å 3 , and Z = 4 at 295 K. Hydrogen bonds are prominent in the crystal structure. The water molecule forms two medium-strength O–H⋯O hydrogen bonds to one of the esylate anions. The protonated nitrogen atom in each cation forms a N–H⋯O hydrogen bond to an esylate anion. The ring N–H groups form strong intramolecular N–H⋯O hydrogen bonds to carbonyl groups. The ring N–H groups form intramolecular N–H⋯O hydrogen bonds to esylate anions. Many C–H⋅⋅⋅O hydrogen bonds (and one C–H⋯N hydrogen bond), with aromatic C–H, methylene groups and methyl groups as donors, are present. The hydrogen bonding patterns of the two cations differ considerably. The powder pattern has been submitted to ICDD for inclusion in the Powder Diffraction File™ (PDF®)
Source: crossref · Quality: baseline
Research context
OpenAlex topics: X-ray Diffraction in Crystallography · Crystallography and molecular interactions · Thermal and Kinetic Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (17)
Show source-provided references
1. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
2. 10.1107/S090904950801843810.1107/S0909049508018438 ↗
3. 10.1021/acs.jctc.2c0095810.1021/acs.jctc.2c00958 ↗
4. 10.1063/1.296926010.1063/1.2969260 ↗
5. 10.3389/fonc.2023.108621410.3389/fonc.2023.1086214 ↗
6. 2024
7. 10.1016/j.molliq.2022.11862410.1016/j.molliq.2022.118624 ↗
8. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
9. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
10. 10.1183/09031936.0017491410.1183/09031936.00174914 ↗
11. Pirfenidone vs. Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: A Retrospective Cohort Study
12. Roth, G. K. , Linz, G. , Sieger, P. , Rall, W. , Hilberg, F. , & Bock, T. . 2006. “3-Z-[1-(4-(N-((4-Methyl-Piperazin-1-yl)Methylcarbonyl)-N-Methylamino)Anilino)-1-Phenylmethylene]-6-Methoxycarbonyl-2-Indolinone Monoethanesulfonate and the Use Thereof as a Pharmaceutical Composition.” United States Patent 7,119,093 B2 (Boehringer Ingelheim Pharma GmbH).
13. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
14. 10.3749/canmin.46.5.150110.3749/canmin.46.5.1501 ↗
15. 10.1017/S088571561900081210.1017/S0885715619000812 ↗
16. Gole, S. & Bankole, A. . 2023. Nintedanib – StatPearls – NCBI Bookshelf. www.ncbi.nlm.nih.gov/books/NBK585049/.
17. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗